Production and evaluation of a new set of recombinant antigens for the serological diagnosis of human cysticercosis.

Autor: Melki J; Department of Parasitology-Mycology, Institut Pasteur de Côte d'Ivoire, Abidjan, Côte d'Ivoire. Electronic address: jihenmelki@gmail.com., Kouadio TN; Department of Parasitology-Mycology, Institut Pasteur de Côte d'Ivoire, Abidjan, Côte d'Ivoire. Electronic address: ndriborel@gmail.com., Nowakowski M; Recombinant Protein Platform, Institut Pasteur, Paris, France. Electronic address: mireille.nowakowski@pasteur.fr., Razafiarimanga Z; Fundamental and Applied Biochemistry, University of Antananarivo, Madagascar. Electronic address: razafiarimanga@gmail.com., Soumahoro MK; Department of Epidemiology, Institut Pasteur de Côte d'Ivoire, Côte d'Ivoire. Electronic address: mksoumahoro@pasteur.ci., Peltres S; Recombinant Protein Platform, Institut Pasteur, Paris, France. Electronic address: stephane.petres@pasteur.fr., Jambou R; Department of Parasitology-Mycology, Institut Pasteur de Côte d'Ivoire, Abidjan, Côte d'Ivoire; Global Health Department, Institut Pasteur, Paris, France. Electronic address: rjambou@pasteur.fr.
Jazyk: angličtina
Zdroj: Experimental parasitology [Exp Parasitol] 2024 Aug-Sep; Vol. 263-264, pp. 108803. Date of Electronic Publication: 2024 Jul 14.
DOI: 10.1016/j.exppara.2024.108803
Abstrakt: Human cysticercosis caused by Taenia soliun (T. soliun) is endemic in certain areas of Latin America, Asia and Sub-Saharan Africa. Neurocysticercosis (NCC) is mainly diagnosed by neuroimaging, which, in most cases, is unavailable in endemic areas. Due to their high sensitivity and specificity, serological tests such as enzyme-linked immunosorbent assay (ELISA) and Western blot (WB) based on the glycosylated fraction of the cyst CS50 are widely used for the detection of the anti-cysticercus IgG antibodies despite their significant cost and the need of cysticercus material. Given their cost-effectivess and simplicity, immunoassays based on recombinant proteins could provide new alternatives for human cysticercosis diagnosis: such tests would be aimed at screening those people living in remote areas who need further examination. To date, however, no test using recombinant antigens is commercially available. Herein, five recombinant proteins (R14, R18, R93.1, R914.1, and R915.2) were produced, three of which (R93.1, R914.1, and R915.2) were newly identified from the cyst fluid. Evaluation of the diagnostic performance of these recombinant antigens by ELISA was done using sera from 200 epileptic and non-epileptic individuals in comparison with the WB-CS50 as the reference serological method. Recombinant proteins-based ELISA showed a level of diagnostic performance that is inferior than the reference serological method, but similar to that of the native antigen ELISA for human cysticercosis (commonly used for screening). Further optimization of expression conditions is still needed in order to improve proteins solubility and enhance diagnostic performance for human cysticercosis detection. However, this preliminary evaluation of the recombinant antigens has shown their potential valuable use for screening cysticercosis in patients with epilepsy attending dispensaries in remote areas. Future studies should be conducted to evaluate our recombinant antigens in a large group of patients with different stages of NCC, and in correlation with imaging findings.
Competing Interests: Declaration of competing interest This manuscript is not accepted for publication or under editorial review for publication elsewhere. No potential competing interest has to be declared and all authors have approved the manuscript for submission.
(Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: